Efficacy News and Research

RSS

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Aeterna Zentaris Inc., today announced positive interim data for the Phase 1 portion of its ongoing Phase 1/2 study in castration and taxane-resistant prostate cancer with its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108.

26 Sep 2011

Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma

Clermont Pharmaceuticals, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today positive results from a phase III trial of non-preserved latanoprost. In the study, non-preserved latanoprost was compared to Xalatan (latanoprost ophthalmic solution) 0.005%, in subjects diagnosed with open-angle glaucoma.

26 Sep 2011

Percutaneous hepatic perfusion extends survival time for melanoma patients

Melanoma of the eye frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients live for a year. Now, final results from a phase III study have demonstrated that a new treatment significantly extends the time patients can live without the disease progressing.

26 Sep 2011

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.

26 Sep 2011

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

A pivotal Phase III study shows Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.

26 Sep 2011

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Patrys Limited has announced that its lead anti-cancer antibody PAT-SM6 has shown significant activity in preclinical studies of multiple myeloma.

26 Sep 2011

Drug combo for breast cancer in post-menopausal women shows promise

Combining two drugs in post-menopausal women with a certain type of advanced breast cancer more than doubled the time they lived without their disease getting worse, a new study data showed.

26 Sep 2011

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhea.

26 Sep 2011

Combination of everolimus, exemestane holds promise against post-menopausal breast cancer

Results from a phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome.

26 Sep 2011

RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. today announced that treatment and follow-up have been completed on 69 patients in the Company's Phase 2 clinical trial with RGN-259 for the treatment of dry eye syndrome, five more than the number of evaluable patients contemplated in the trial's protocol.

26 Sep 2011

Janssen Biotech receives FDA approval for Remicade to treat UC in children

The U.S. Food and Drug Administration today approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children older than 6 years who have had inadequate response to conventional therapy.

26 Sep 2011

Letrozole reduces risk of breast cancer recurrences and death in post-menopausal women

Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer.

26 Sep 2011

Gilead announces EMA CHMP positive opinion for HIV-1 drug, Eviplera

Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company's Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera.

23 Sep 2011

Synthetic lectins inhibit HIV from entering cells

University of Utah researchers have discovered a new class of compounds that stick to the sugary coating of the AIDS virus and inhibit it from infecting cells - an early step toward a new treatment to prevent sexual transmission of the virus.

23 Sep 2011

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

Astellas Pharma Europe Ltd. (APEL) and Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhoea (CDAD).

23 Sep 2011

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

YM BioSciences Inc., a drug development company advancing a diverse portfolio of promising hematology and cancer-related products, today reported operational and financial results for its 2011 fiscal year, ended June 30, 2011.

23 Sep 2011

Soy protein reduces progression of atherosclerosis in women within 5 years of menopause

A new study published in the November 2011 issue of Stroke reveals some promising data on the positive effects of soy protein reducing the progression of clogged arteries in women who were within five years of menopause. This study was the largest and longest randomized controlled human study conducted to-date that directly investigated the efficacy of isolated soy protein consumption on the progression of atherosclerosis.

23 Sep 2011

STAAR's new Visian ICL with CentraFLOW technology showcased at ESCRS congress

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced the Visian Implantable Collamer Lens (ICL), and new Visian ICL with CentraFLOW technology utilizing the KS-AquaPORT, were featured prominently in twice as many presentations at the 2011 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) as those on the ICL during last year's Congress.

23 Sep 2011

New microbicide may block AIDS virus from infecting cells

23 Sep 2011

Shire announces update on approval status and availability of ProAmatine SOH drug

Shire plc, the global specialty biopharmaceutical company, announces an update on the approval status and availability of ProAmatine (midodrine HCl), a medicine approved for the treatment of symptomatic orthostatic hypotension.

23 Sep 2011

Efficacy News and Research

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma

Percutaneous hepatic perfusion extends survival time for melanoma patients

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Drug combo for breast cancer in post-menopausal women shows promise

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

Combination of everolimus, exemestane holds promise against post-menopausal breast cancer

RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome

Janssen Biotech receives FDA approval for Remicade to treat UC in children

Letrozole reduces risk of breast cancer recurrences and death in post-menopausal women

Gilead announces EMA CHMP positive opinion for HIV-1 drug, Eviplera

Synthetic lectins inhibit HIV from entering cells

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

Soy protein reduces progression of atherosclerosis in women within 5 years of menopause

STAAR's new Visian ICL with CentraFLOW technology showcased at ESCRS congress

New microbicide may block AIDS virus from infecting cells

Shire announces update on approval status and availability of ProAmatine SOH drug

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News